Day One Biopharmaceuticals (NASDAQ:DAWN) Given Neutral Rating at HC Wainwright

HC Wainwright restated their neutral rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The firm currently has a $21.50 price target on the stock, down from their previous price target of $22.00.

Several other research analysts have also weighed in on DAWN. Needham & Company LLC lowered Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 6th. Zacks Research lowered Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. JonesTrading cut Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and boosted their price target for the company from $20.00 to $21.50 in a research note on Friday, March 6th. Wedbush restated a “neutral” rating and issued a $21.50 price objective (down from $30.00) on shares of Day One Biopharmaceuticals in a report on Monday. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Hold” and an average price target of $24.44.

Day One Biopharmaceuticals Stock Down 0.2%

Day One Biopharmaceuticals stock opened at $21.28 on Tuesday. The company’s fifty day simple moving average is $11.59 and its 200-day simple moving average is $9.28. Day One Biopharmaceuticals has a 12 month low of $5.64 and a 12 month high of $21.43. The stock has a market cap of $2.20 billion, a P/E ratio of -20.66 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The firm had revenue of $53.72 million for the quarter, compared to analysts’ expectations of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. On average, equities research analysts expect that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 15,459 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $179,324.40. Following the transaction, the chief executive officer directly owned 204,603 shares in the company, valued at $2,373,394.80. This trade represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Charles N. York II sold 6,065 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $70,354.00. Following the sale, the chief financial officer owned 312,025 shares of the company’s stock, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 36,461 shares of company stock valued at $422,948. Insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC bought a new position in Day One Biopharmaceuticals in the 3rd quarter worth $10,719,000. AlphaQuest LLC boosted its holdings in Day One Biopharmaceuticals by 1,065.6% during the third quarter. AlphaQuest LLC now owns 185,006 shares of the company’s stock valued at $1,304,000 after acquiring an additional 169,134 shares during the period. Schroder Investment Management Group bought a new stake in Day One Biopharmaceuticals during the second quarter valued at about $1,171,000. Geode Capital Management LLC grew its position in shares of Day One Biopharmaceuticals by 11.2% in the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock valued at $11,132,000 after purchasing an additional 171,964 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its position in shares of Day One Biopharmaceuticals by 71.7% in the second quarter. Dynamic Technology Lab Private Ltd now owns 83,223 shares of the company’s stock valued at $541,000 after purchasing an additional 34,766 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

Key Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Servier offered to buy Day One for $21.50 per share in a reported $2.5B deal, adding the company’s brain tumor drug Ojemda and oncology assets — this is the primary reason for the recent sharp jump in DAWN’s share price. Zacks: DAWN Stock Jumps on Buyout Offer
• Neutral Sentiment: Short‑interest reports published this week appear to show large increases but list 0 shares/NaN values and 0.0 days to cover — the data look anomalous and aren’t providing reliable evidence of a true short squeeze or covering pressure.
• Neutral Sentiment: H.C. Wainwright reaffirmed a “Neutral” rating with a $21.50 target (down from $22), leaving implied upside minimal versus the current deal price; the note treats the stock as fairly valued at the takeover level. Street Insider: H.C. Wainwright
• Negative Sentiment: Several firms (Wedbush, Needham, JonesTrading and others) have cut DAWN to “Hold”/“Neutral” and trimmed price targets — these analyst moves reflect skepticism about incremental upside beyond the offer price and may cap speculative buying. MSN: Wedbush Downgrades AmericanBankingNews: JonesTrading AmericanBankingNews: Needham
• Negative Sentiment: A PR piece flagged potential conflicts and questions about whether insiders stand to receive outsized benefits under the proposed transactions — such governance/fairness concerns could prompt shareholder scrutiny or legal pushback that delays or alters the deal. PR Newswire: Deal Fairness Questions

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.